Oxyprim Gout Therapy To Be Limited To Allopurinol Failures, Cardiome Says
Executive Summary
Cardiome's risk management plan for the chronic gout therapy Oxyprim would require proof of patient failure on standard therapy before administration, Exec VP-Clinical Development Alan Moore, PhD, said June 2
You may also be interested in...
Takeda Febuxostat Benefits Outweigh CV Risk; Will Other Gout Drugs Follow?
Strong efficacy data and a desperate need for new gout therapies outweigh the potential cardiovascular risk associated with Takeda's febuxostat, an FDA advisory committee determined in recommending approval of the drug during a Nov. 24 meeting
Takeda Febuxostat Benefits Outweigh CV Risk; Will Other Gout Drugs Follow?
Strong efficacy data and a desperate need for new gout therapies outweigh the potential cardiovascular risk associated with Takeda's febuxostat, an FDA advisory committee determined in recommending approval of the drug during a Nov. 24 meeting
Cardiome Oxyprim is “approvable”
Cardiome is assessing whether to continue development of Oxyprim (oxypurinol) for allopurinol-intolerant hyperuricemia following an FDA "approvable" letter. FDA Arthritis Advisory Committee expressed dissatisfaction with the protocol for the pivotal Phase II trial during a June 2 meeting (1"The Pink Sheet" June 7, 2004, p. 40)...